Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ARSA | P15289 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | CDC25C | P30307 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081576 | 0.80 | ARSA (0.56) | ALDH1A1KDM4EHTTKMT2APOLB | |
| SCHEMBL29627465 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4EHTTKMT2APOLB | |
| SCHEMBL3617428 | 0.79 | ALDH1A1 (0.54) | ALDH1A1KDM4EHTTKMT2APOLB | |
| SCHEMBL3585903 | 0.78 | CES1 (0.48) | ALDH1A1KDM4EKMT2APOLBTDP1 | |
| SCHEMBL17384172 | 0.77 | HPRT1 (0.56) | ALDH1A1KDM4EHTTKMT2AARSA | |
| SCHEMBL17384169 | 0.77 | HPRT1 (0.56) | ALDH1A1KDM4EHTTKMT2AARSA | |
| SCHEMBL3585905 | 0.75 | ALDH1A1 (0.38) | ALDH1A1KDM4EKMT2APOLBESR1 | |
| SCHEMBL3579721 | 0.74 | LMNA (0.41) | ALDH1A1KDM4EKMT2APOLBESR1 | |
| SCHEMBL7915211 | 0.74 | KDM4E (0.61) | ALDH1A1KDM4EHTTKMT2APOLB | |
| SCHEMBL31360532 | 0.73 | HPRT1 (0.44) | ALDH1A1KDM4EHTTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795299-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| EP-1722779-A4 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | UNIV NORTH CAROLINA (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7495026-B2 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1722779-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | The University of North Carolina at Chapel Hill (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050250751-A1 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005087225-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118356-A1 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS | BRCA1, CYP19A1, HUNK | ALDH1A1 1537/4885KDM4E 3729/4885HTT 3748/4885 |
| US-20050250751-A1 | Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | BRCA1, CYP19A1, CYP51A1 | ALDH1A1 1521/4885KDM4E 3932/4885HTT 3909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.